JP2015530081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015530081A5 JP2015530081A5 JP2015524573A JP2015524573A JP2015530081A5 JP 2015530081 A5 JP2015530081 A5 JP 2015530081A5 JP 2015524573 A JP2015524573 A JP 2015524573A JP 2015524573 A JP2015524573 A JP 2015524573A JP 2015530081 A5 JP2015530081 A5 JP 2015530081A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- cancer
- stem cells
- cells
- rna aptamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008103 RNA aptamers Proteins 0.000 claims 13
- 210000000130 stem cell Anatomy 0.000 claims 11
- 108091023037 Aptamer Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 7
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 7
- 229940039227 diagnostic agent Drugs 0.000 claims 5
- 239000000032 diagnostic agent Substances 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940124447 delivery agent Drugs 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000010562 histological examination Methods 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012857 radioactive material Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012903333 | 2012-08-02 | ||
| AU2012903333A AU2012903333A0 (en) | 2012-08-02 | EpCAM Aptamer for Detection of Cancer Stem Cells | |
| PCT/AU2013/000851 WO2014019025A1 (en) | 2012-08-02 | 2013-08-02 | Epcam aptamer for detection of cancer stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015530081A JP2015530081A (ja) | 2015-10-15 |
| JP2015530081A5 true JP2015530081A5 (enExample) | 2016-09-23 |
| JP6297034B2 JP6297034B2 (ja) | 2018-03-20 |
Family
ID=50026988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524573A Active JP6297034B2 (ja) | 2012-08-02 | 2013-08-02 | 癌幹細胞を検出するためのＥｐＣＡＭアプタマー |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9567586B2 (enExample) |
| EP (1) | EP2880163B1 (enExample) |
| JP (1) | JP6297034B2 (enExample) |
| KR (1) | KR20150083075A (enExample) |
| CN (1) | CN104854243B (enExample) |
| AU (1) | AU2013299332B2 (enExample) |
| BR (1) | BR112015002286A2 (enExample) |
| CA (1) | CA2880590C (enExample) |
| HK (1) | HK1213941A1 (enExample) |
| IL (1) | IL237038A0 (enExample) |
| IN (1) | IN2015DN00636A (enExample) |
| MX (1) | MX2015001441A (enExample) |
| NZ (1) | NZ704718A (enExample) |
| SG (1) | SG11201500663RA (enExample) |
| WO (1) | WO2014019025A1 (enExample) |
| ZA (1) | ZA201501317B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022165286A1 (en) * | 2021-01-29 | 2022-08-04 | Base Pair Biotechnologies, Inc. | Functional ligands to pertussis toxin |
| EP3185910A4 (en) | 2014-08-29 | 2018-01-10 | Children's Medical Center Corporation | Methods and compositions for the treatment of cancer |
| KR101641920B1 (ko) * | 2014-09-05 | 2016-07-22 | 한국생명공학연구원 | EpCAM에 특이적으로 결합하는 핵산 앱타머 및 이의 용도 |
| ES2796504T3 (es) * | 2015-02-11 | 2020-11-27 | Univ Deakin | Aptámeros de EpCAM y conjugados de los mismos |
| CN105779458B (zh) * | 2016-03-23 | 2020-03-17 | 苏州方舟生物医药有限公司 | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 |
| CN107875140A (zh) * | 2016-09-30 | 2018-04-06 | 复旦大学 | 一种双靶向药物递送系统及其在制备肿瘤治疗制剂中的应用 |
| WO2019018497A1 (en) * | 2017-07-18 | 2019-01-24 | President And Fellows Of Harvard College | INTRACELLULAR DELIVERY USING MICROFLUIDIC ASSISTED CELLULAR SCREENING (MACS) |
| KR102212149B1 (ko) * | 2019-03-28 | 2021-02-04 | 부산대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도 |
| CN110184272B (zh) * | 2019-04-01 | 2021-03-30 | 福州大学 | 一种新型环状三元适配体及其合成方法和应用 |
| WO2020257401A1 (en) * | 2019-06-21 | 2020-12-24 | The Children's Medical Center Corporation | Methods and compositions for the treatment of cancer |
| CN110261359B (zh) * | 2019-06-27 | 2022-01-28 | 复旦大学 | 一种基于激光共聚焦显微镜的癌症标志物成像方法 |
| CN110592093B (zh) * | 2019-09-10 | 2023-08-25 | 上海交通大学医学院附属仁济医院 | 一种能够识别EpCAM蛋白的核酸适体及其制备方法与应用 |
| EP3868884A1 (en) * | 2020-02-19 | 2021-08-25 | Aarhus Universitet | Method for subtyping bladder cancer using aptamers |
| KR102685696B1 (ko) * | 2020-06-03 | 2024-07-16 | 한국생명공학연구원 | 암 전이 및 재발 진단용 조성물 |
| US20240240178A1 (en) * | 2021-05-06 | 2024-07-18 | Systems Oncology, Llc | Sirna constructs for inhibiting gene expression in targeted cancer cells |
| CN114990124B (zh) * | 2022-06-22 | 2023-09-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 膜蛋白靶标cd44的核酸适配体、其筛选方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100105104A1 (en) * | 2007-03-05 | 2010-04-29 | On-Chip Cellomics Consortium | Chip for sampling cell component, system for analyzing cell component and method of analyzing cell component using the same |
| EP2159286A1 (en) * | 2008-09-01 | 2010-03-03 | Consiglio Nazionale Delle Ricerche | Method for obtaining oligonucleotide aptamers and uses thereof |
| WO2013003898A1 (en) | 2011-07-07 | 2013-01-10 | Clinical Genomics Pty. Ltd | Method for detection of cancer in a patient |
-
2013
- 2013-08-02 BR BR112015002286A patent/BR112015002286A2/pt not_active Application Discontinuation
- 2013-08-02 US US14/418,660 patent/US9567586B2/en active Active
- 2013-08-02 NZ NZ704718A patent/NZ704718A/en unknown
- 2013-08-02 EP EP13825695.3A patent/EP2880163B1/en active Active
- 2013-08-02 CN CN201380050791.2A patent/CN104854243B/zh active Active
- 2013-08-02 HK HK16101899.2A patent/HK1213941A1/zh unknown
- 2013-08-02 KR KR1020157005475A patent/KR20150083075A/ko not_active Withdrawn
- 2013-08-02 JP JP2015524573A patent/JP6297034B2/ja active Active
- 2013-08-02 WO PCT/AU2013/000851 patent/WO2014019025A1/en not_active Ceased
- 2013-08-02 SG SG11201500663RA patent/SG11201500663RA/en unknown
- 2013-08-02 IN IN636DEN2015 patent/IN2015DN00636A/en unknown
- 2013-08-02 MX MX2015001441A patent/MX2015001441A/es unknown
- 2013-08-02 AU AU2013299332A patent/AU2013299332B2/en active Active
- 2013-08-02 CA CA2880590A patent/CA2880590C/en active Active
-
2015
- 2015-02-01 IL IL237038A patent/IL237038A0/en unknown
- 2015-02-26 ZA ZA2015/01317A patent/ZA201501317B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015530081A5 (enExample) | ||
| JP2015526075A5 (enExample) | ||
| Senthebane et al. | The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices | |
| Mao et al. | Nidogen 1‐enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1 | |
| Arif et al. | Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets | |
| Zhang et al. | Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma | |
| Zhang et al. | Hypoxia-responsive lncRNA AC115619 encodes a micropeptide that suppresses m6A modifications and hepatocellular carcinoma progression | |
| Hori et al. | Current advances in aptamers for cancer diagnosis and therapy | |
| Inder et al. | Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation | |
| Mao et al. | Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1 | |
| Mi et al. | In vivo selection against human colorectal cancer xenografts identifies an aptamer that targets RNA helicase protein DHX9 | |
| Cheng et al. | A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies | |
| Wang et al. | Carbon dots based two-photon visible nanocarriers for safe and highly efficient delivery of siRNA and DNA | |
| Boj et al. | Organoid models of human and mouse ductal pancreatic cancer | |
| Wu et al. | Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo | |
| Casalino et al. | The Fra-1/AP-1 oncoprotein: from the “Undruggable” transcription factor to therapeutic targeting | |
| Kim et al. | PET imaging of HER2 expression with an 18F-fluoride labeled aptamer | |
| CN103387988A (zh) | 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法 | |
| Vallabhaneni et al. | Stromal cell extracellular vesicular cargo mediated regulation of breast cancer cell metastasis via ubiquitin conjugating enzyme E2 N pathway | |
| Xu et al. | N6‐methyladenosine modification of CENPF mRNA facilitates gastric cancer metastasis via regulating FAK nuclear export | |
| Chen et al. | Long noncoding RNA GAS5 inhibits metastasis by targeting miR-182/ANGPTL1 in hepatocellular carcinoma | |
| US20120142013A1 (en) | Nucleic acid aptamer capable of binding specifically to pancreatic cancer cells or tissues and use thereof | |
| JP2015513919A5 (enExample) | ||
| Azman et al. | An ERK1/2‐driven RNA‐binding switch in nucleolin drives ribosome biogenesis and pancreatic tumorigenesis downstream of RAS oncogene | |
| Solé et al. | MicroRNAs and metastasis |